Celldex Therapeutics (CLDX) Income towards Parent Company (2010 - 2026)

Celldex Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$85.9 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 37.12% year-over-year to -$85.9 million in Q1 2026; TTM through Mar 2026 was -$326.8 million, a 34.59% increase from a year earlier, with the FY2025 full-year figure at -$661.6 million, down 38.51% from the prior year.
• Income towards Parent Company rose to -$85.9 million in Q1 2026 per CLDX's latest filing, from -$109.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$23.0 million in Q1 2022 and bottomed at -$390.7 million in Q4 2023.
• The 5-year median for Income towards Parent Company is -$47.7 million (2024), against an average of -$87.0 million.
• Across the five-year window, Income towards Parent Company tumbled 1375.03% in 2023 and jumped 67.81% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$26.5 million in 2022, then tumbled by 1375.03% to -$390.7 million in 2023, then rose by 12.83% to -$340.5 million in 2024, then soared by 67.81% to -$109.6 million in 2025, then increased by 21.63% to -$85.9 million in 2026.
• Per Business Quant, the three latest CLDX Income towards Parent Company figures stand at -$85.9 million (Q1 2026), -$109.6 million (Q4 2025), and -$67.0 million (Q3 2025).